Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03148795 |
| A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer |
| completed |
| Phase 2 |
| 128 |
| PfizerINDUSTRY |
| 14 |
| Apr 5, 2024 |
| clinicaltrials |
| NCT02325557 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 / Phase 2 | 50 | Advaxis, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03311555 | A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) | completed | Phase 2 | 39 | Andrew J. Armstrong, MDOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT01759771 | Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial(VD3PCa) | completed | Phase 2 | 130 | VA Office of Research and DevelopmentFED | 1 | Mar 18, 2024 | clinicaltrials |
| NCT02280356 | Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer | completed | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03554317 | COMbination of Bipolar Androgen Therapy and Nivolumab(COMBAT-CRPC) | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03388346 | 68Ga PSMA in Preprostatectomy Patients | completed | Phase 2 / Phase 3 | 22 | Michael Graham PhD, MDOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT00946881 | Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 30 | Steba Biotech S.A.OTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02903160 | Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | completed | Phase 2 | 40 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03651271 | Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer | completed | Phase 2 | 100 | Parker Institute for Cancer ImmunotherapyOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT02543255 | Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)(ACDC-RP) | completed | Phase 2 | 76 | University Health Network, TorontoOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT03698370 | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | completed | Phase 2 | 27 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT03949517 | 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy | completed | Phase 1 / Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01704274 | GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy(GTN) | completed | Phase 2 | 43 | Dr. D. Robert SiemensOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03809078 | 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer | completed | Phase 2 | 14 | Andrei IagaruOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT03113617 | 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | completed | Phase 2 | 44 | Andrei IagaruOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT00915122 | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate | completed | Phase 1 / Phase 2 | 81 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT00818623 | Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients | completed | Phase 2 | 172 | Ferring PharmaceuticalsINDUSTRY | 7 | Nov 30, 2023 | clinicaltrials |
| NCT00819156 | Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer | completed | Phase 2 | 189 | Ferring PharmaceuticalsINDUSTRY | 8 | Nov 30, 2023 | clinicaltrials |
| NCT00584532 | Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.(GCP) | completed | Phase 2 / Phase 3 | 66 | University of California, DavisOTHER | 0 | Nov 24, 2023 | clinicaltrials |
| NCT03513211 | Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer(HITMAN-PC) | completed | Phase 1 / Phase 2 | 12 | St Vincent's Hospital, SydneyOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT00819247 | The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer | completed | Phase 2 | 129 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT00587431 | Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer | completed | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT03396874 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | completed | Phase 2 | 1,435 | University of MichiganOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT00337155 | BAY88-8223, Dose Finding Study in Patients With HRPC | completed | Phase 2 | 122 | BayerINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT00020046 | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT01956058 | Brachytherapy for Recurrent Prostate Cancer(CAPRICUR) | completed | Phase 2 | 30 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03830164 | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00736645 | Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 55 | Roswell Park Cancer InstituteOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT01867333 | Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05613842 | Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)(BOP) | completed | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01607879 | Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation | completed | Phase 2 | 48 | Medical College of WisconsinOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05516329 | Study of 18F-Thretide PET/CT in Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT01485861 | Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | completed | Phase 1 / Phase 2 | 298 | Genentech, Inc.INDUSTRY | 9 | Sep 14, 2023 | clinicaltrials |
| NCT01558427 | Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | completed | Phase 2 | 62 | University Hospital, GhentOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04614363 | 68 Ga-PSMA for High Risk Prostate Cancer | completed | Phase 1 / Phase 2 | 80 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT00668642 | Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer | completed | Phase 2 | 20 | Endeavor HealthOTHER | 1 | Aug 22, 2023 | clinicaltrials |
| NCT01331083 | A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 68 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT00002889 | Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer | completed | Phase 2 | 180 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT00093457 | Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer | completed | Phase 2 | 28 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT00258388 | Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | completed | Phase 2 | 82 | NCIC Clinical Trials GroupNETWORK | 2 | Aug 4, 2023 | clinicaltrials |
| NCT01075308 | SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer | completed | Phase 2 | 32 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT01619813 | Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 85 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04936334 | The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer | completed | Phase 2 | 51 | Clinton BahlerOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01666808 | FACBC Outcomes for Post Prostatectomy | completed | Phase 2 / Phase 3 | 165 | Emory UniversityOTHER | 1 | Aug 2, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Apr 17, 2024source: clinicaltrials